Karna D Shinde invests in Navaux’s cancer detection technology

Karna D Shinde, an early-stage angel investor, has made an undisclosed investment in Navaux, a life science company based in Arkansas, USA.

Navaux specializes in early cancer detection and treatment monitoring, utilizing a cutting-edge blood test called ACTIVH. 

Navaux's ACTIVH Test

Navaux's ACTIVH test, developed from extensive preclinical studies, can predict the onset of cancer up to 3-4 years in advance. This early detection allows individuals to make crucial lifestyle changes that could potentially prevent cancer development.

The test is noninvasive, quick, and easy, involving a simple blood draw to detect elevated Hepsin levels, which indicate the presence of tumors.

"ACTIVH is more affordable and accessible than traditional methods, making proactive health management feasible for more individuals," the company said.

Impact on cancer treatment

The ACTIVH test is not only a tool for early detection but also plays a critical role in monitoring ongoing cancer treatments.

By tracking Hepsin levels in the blood, the test provides real-time insights into the efficacy of therapies like chemotherapy and radiation. A decrease in Hepsin levels signals effective treatment, while an increase suggests the need for alternative therapies. 

"Early cancer detection significantly improves survival rates. Navaux's ACTIVH is a boon for patients and their families," said Karna D Shinde.

Strategic Investment in the Indian Market

India is rapidly becoming a hub for health-tech innovations, a trend emphasized by Finance Minister Nirmala Sitharaman’s recent Union Budget 2024-25 announcement. This budget exempts three crucial cancer treatment medicines from customs duty, aiming to improve access to essential treatments.

"This investment will play a pivotal role in helping Navaux establish connections within the Indian healthcare industry as they prepare to introduce their cutting-edge solutions to the Indian market," Navaux said in a statement.

Future Prospects

Karna D Shinde's investment in Navaux goes beyond financial support. His involvement includes providing insights and a hands-on approach, which are invaluable to the company's growth.

Don Fowler, CEO of Navaux, emphasized the transformative impact of this partnership. "Karna’s involvement has been instrumental in advancing our technology and reaching new markets."

Navaux is also set to present new preclinical and clinical data on the prognostic potential of circulating Hepsin at the American Association for Cancer Research (AACR).

The presentation is expected to further validate the effectiveness of the ACTIVH test and highlight its potential in revolutionizing cancer detection and treatment monitoring globally.